Adecto Pharmaceuticals, Inc.

BROOKLINE, MA 02446

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $413K
First Award Date 04/15/16
Most Recent Award Date 01/12/17

Key Personnel

Last Name Name Awards Contact
SONENSHEIN GAIL E SONENSHEIN 3

3 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 01/12/17 - 04/14/17

? DESCRIPTION (provided by applicant): Triple-negative breast cancers (TNBCs) account for ~25% of breast cancer deaths and lack targeted therapies. Drs. Sonenshein, Mineva and Romagnoli and their co-workers recently identified the non-essential, cell surface protein ADAM8 (A Disintegrin and Metalloprotease 8) as a pivotal promoter of breast t...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 09/19/16 - 04/14/17

Triple-negative breast cancers (TNBCs) account for ~25% of breast cancer deaths and lack targeted therapies. Drs. Sonenshein, Mineva and Romagnoli and their co-workers recently identified the non-essential, cell surface protein ADAM8 (A Disintegrin And Metalloprotease 8) as a pivotal promoter of breast tumor growth and metastasis, and validated ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 04/15/16 - 04/14/17

? DESCRIPTION (provided by applicant): Triple-negative breast cancers (TNBCs) account for ~25% of breast cancer deaths and lack targeted therapies. Drs. Sonenshein, Mineva and Romagnoli and their co-workers recently identified the non-essential, cell surface protein ADAM8 (A Disintegrin and Metalloprotease 8) as a pivotal promoter of breast t...